First phase study

The second part of our 1st phase study has just been successfully completed with no Serious Adverse Events.

Drug administration was performed on ECU, where Subjects were provided with carefull medical care. As a standard, Team of Specialists (Anesthesiologist, Psychiatrist, two Investigators and Nurses) was present during the procedure just to assure maximum safety and quality of recorded data. Vital signs of the Subjects were constantly monitored (BP holter and ECG monitoring) and assessed by a Physician.

Go back

News

BRG team participated in BIO-Europe®

On 26th -27th  of October BRG team participated in BIO-Europe® the largest partnering conference in Europe dedicated to the global biotechnology industry. 

Read more …

BRG Team participated in the official opening of the Celon Pharma Research and Development Center

On September 28, 2020 BRG Team participated in the official opening of the Celon Pharma Research and Development Center

Read more …

Dr Jarosław Długołęcki

We are pleased to welcome a new member of the BRG medical expert team. Mr Jarosław Długołęcki, (M.D.) - doctor with extensive knowledge and 16-years’ experience in clinical studies at the international level.

Read more …

Badania kliniczne faz wczesnych szczepionek – wyzwania w obliczu nowych zagrożeń

Szczepienia ochronne niezaprzeczalnie należą do jednych z najbardziej przełomowych odkryć nowoczesnej medycyny.

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2026 © Bio Research Group. All rights reserved.

 

scroll to top ▲